目的 构建透明质酸(hyaluronan hyaluronic acid,HA)功能化MCM-41型介孔二氧化硅纳米粒(MCM-41)包载紫杉醇(paclitaxel,PTX)的靶向药物递送系统(HA-MCM-41-PTX)。考察其理化性质、体外释药行为及体外肿瘤抑制效果。方法 通过透射电镜考察MCM-41的形态结构及粒径,粉末X射线衍射法和傅里叶红外光谱法对载药体系进行表征,体外溶出实验考察载药体系的体外释放行为,体外细胞实验探究载药体系对SMMC-7721细胞的作用机制。结果 HA-MCM-41-PTX载药量为26.75%。体外释药呈缓释,48 h药物累积释放量为(86.19±5.11)%。细胞实验表明,载药体系具有靶向作用,易被细胞摄入并表现出良好的肿瘤细胞抑制作用。结论 HA-MCM-41-PTX是同时具有缓释性和靶向性的载药体系。
Abstract
OBJECTIVE To establish a drug delivery system based on hyaluronic acid functionalized mesoporous silica nanoparticles MCM-41 loaded with paclitaxel (HA-MCM-41-PTX). The physical and chemical properties, in vitro drug release and the antitumor effect were investigated. METHODS The morphological structure and particle size of MCM-41 were observed by TEM. The drug delivery system was characterized by PXRD and FTIR. The in vitro release experiments was carried out to investigate the dissolution rate of HA-MCM-41-PTX. The in vitro cells experiment was carried out to explore the mechanism of HA-MCM-41-PTX on cells. RESULTS The drug loading capacity of HA-MCM-41-PTX was 28.75%. The in vitro drug release experiments showed that HA-MCM-41-PTX exhibited controlled release with a cumulative release of (86.19±5.11)% until 48 h. In vitro cell experiments showed that HA-MCM-41-PTX had excellent targeting effect due to the modification of hyaluronic acid, which was easier to be uptaken by cells and exhibited great antitumor effect. CONCLUSION HA-MCM-41-PTX is an excellent drug delivery system with both controlled release and targeting antitumor effect.
关键词
透明质酸 /
介孔二氧化硅 /
SMMC-7721肝癌细胞 /
紫杉醇 /
肿瘤
{{custom_keyword}} /
Key words
hysluronic acid /
mesoporous silica /
SMMC-7721 hepatocillular carcinoma cell /
paclitaxel /
tumor
{{custom_keyword}} /
中图分类号：
R944
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SIEGEL R L, MILLER K D, AHMEDIN J. Cancer statistics, 2017 [J]. CA Cancer J Clin,2017,67(1):7-30.
[2] BEGLEY C G, ELLIS L M. Drug development: raise standards for preclinical cancer research [J]. Nature,2012,483(7391):531-533.
[3] YANG X Y, SHI X Q, JI J B, et al. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor [J]. Drug Deliv,2018,25(1):780-796.
[4] ZHAO Q F, LIU J, ZHU W Q, et al. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells [J]. Acta Biomater, 2015,23:147-156.
[5] LU Y, LI Y, WU W. Injected nanocrystals for targeted drug delivery [J]. Acta Pharm Sin B(药学学报英文), 2016,6(2):106-113.
[6] NAIRI V, MAGNOLIA S, PILUDU M, et al. Mesoporous silica nanoparticles functionalized with hyaluronic acid.Effect of the biopolymer chain length on cell internalization [J]. Colloids Surfaces B:Biointerfaces,2018,168(1):50-59.
[7] CHEN C, SUN W, WANG X L, et al. pH-responsive nanoreservoirs based on hyaluronic acid end-capped mesoporous silica nanoparticles for targeted drug deliver [J]. Int J Biolo Macromol,2018,111(5):1106-1115.
[8] MOHAOATRA S, ROUT S R, NARAYAN R, et al. Multifunctional mesoporous hollow silica nanocapsules for targeted co-delivery of cisplatin-pemetrexed and MR imaging [J]. Dalton Trans,2014,43(42):15841-15850.
[9] BI Y P, WU C N, XIN M, et al. Facile large-scale preparation of mesoporous silica microspheres with the assistance of sucrose and their drug loading and releasing properties[J]. Int J Pharm,2016,500(1-2):77-84.
[10] QU X Y, ZOU Y, HE C Y, et al. Improved intestinal absorption of paclitaxel by mixed micelles self-assembled from vitamin E succinate-based amphiphilic polymers and their transcellular transport mechanism and intracellular trafficking routes [J]. Drug Deliv,2018,25(1):210-225.
[11] XU X Y, WU C, BAI A D, et al. Folate functionalized mesoporous silica nanoparticles as a liver tumor-targeted drug delivery system for improving the antitumor effect of paclitaxel [J]. J Nanomater,2017:1-13.
[12] WAN L, WANG X F, ZHU W Q, et al. Folate-polyethyleneimine functionalized mesoporous carbon nanoparticles for enhancing oral bioavailability of paclitaxel [J]. Int J Pharm, 2015,484(1-2):207-217.
[13] LI J, MIAO X Q, CHEN T K, et al. Preparation and characterization of pelletized solid dispersion of resveratrol with mesoporous silica microparticles to improve dissolution by fluid-bed coating techniques [J]. Asian J Pharm Sci, 2016,11(4):528-535.
[14] ZHANG J, SUN Y J, TIAN B C, et al. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin [J]. Colloids Surfaces B:Biointerfaces,2016,144(4):293-302.
[15] GHOSH S C, NESLIHAN A S, KLOSTERGAARD J.CD44: a validated target for improved delivery of cancer therapeutics [J]. Expert Opin Ther Targets,2012,16(7):635-650.
[16] HUANG G L, HUANG H L. Application of hyaluronic acid as carriers in drug delivery [J]. Drug Deliv,2018,25(1):766-772.
[17] LV Y Q, XU C R, LIN C S, et al. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and and cancer cells [J]. ACS Nano,2018,12(2):1519-1536.
[18] JIANG H P, SHI X Y, YU X Y, et al. Hyaluronidase enzyme-responsive targeted nanoparticle for effective delivery of 5-fluorouracil in colon cancer [J]. Pharm Res,2018,35(4):73.
[19] ZHANG M Z, XU C L, WEN L Q, et al. A hyaluronidase responsive nanoparticle-based drug delivery system for targeting colon cancer cells [J]. Cancer Res,2016,76(24):7208-7218.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(2542 KB)
